
As an Amazon Associate and affiliate partner, Menrva Books earns from qualifying purchases. Learn more
The term health technology refers to drugs, devices, and programs that can improve and extend quality of life. As decision-makers struggle to find ways to reduce costs while improving health care delivery, health technology assessments (HTA) provide the evidence required to make better-informed decisions. This is the first book that focuses on the statistical options of HTAs, to fully capture the value of health improvements along with their associated economic consequences. After reading the book, readers will better understand why some health technologies receive regulatory or reimbursement approval while others do not, what can be done to improve the chances of approval, as well as common shortcomings of submissions for drug and device reimbursement. The book begins by contrasting the differences between regulatory approval and reimbursement approval. Next, it reviews the principles and steps for conducting an HTA, including the reasons why different agencies will have a different focus for their scope in the HTA. Supplying an accessible introduction to the various statistical options for different methods in an HTA, the book identifies the links to regulatory and reimbursement decisions for each option. It highlights many of the methodological advances that have occurred since HTA research began, to provide researchers and decision-makers with a cutting-edge framework. It also details the logical basis for the methods along with simple instructions on how to conduct the various techniques. Both authors have considerable experience in generating evidence for submissions and reviewing submissions to decision-makers for funding. One of the authors has also received a nationally recognized lifetime achievement award in this area.
This book provides a comprehensive guide to Health Technology Assessment (HTA), focusing on the critical role of biostatistics in navigating the complex landscape of adopting new medicines. It addresses the challenges faced by decision-makers in balancing cost reduction with healthcare improvement, offering evidence-based insights for better-informed choices regarding regulatory and reimbursement approvals. The authors, with extensive experience in evidence generation and submission review, detail the principles, steps, and statistical options for conducting HTAs, highlighting methodological advances and their links to approval decisions.
This text is positioned as a foundational resource for understanding the statistical underpinnings of Health Technology Assessment, particularly relevant for professionals involved in drug and device submissions. Its focus on biostatistics aims to equip readers with the knowledge to interpret and improve the chances of regulatory and reimbursement approval. The authors' combined experience suggests a practical and authoritative approach to the subject matter, detailing both the theoretical framework and the practical application of HTA methods.
Page Count:
276
Publication Date:
2021-06-30
Publisher:
Taylor & Francis Group
ISBN-10:
1032098716
ISBN-13:
9781032098715
No comments yet. Be the first to share your thoughts!